Veterinary Medicines

Nobivac DHP Lyofilisaat en oplosmiddel voor suspensie voor injectie

Authorised
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine parvovirus, strain 154, Live
  • Canine distemper virus, strain Onderstepoort, Live
Download as PDF

Product identification

Medicine name:
Nobivac DHP Lyofilisaat en oplosmiddel voor suspensie voor injectie
Nobivac DHP Lyophilisat et solvant pour suspension injectable
Nobivac DHP Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine parvovirus, strain 154, Live
  • Canine distemper virus, strain Onderstepoort, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan LPV3, Live
    4.00
    log10 50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain 154, Live
    7.00
    log10 50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain Onderstepoort, Live
    4.00
    log10 50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Nobivac DHP Lyophilisate and solvent for suspension for injection 10 vials with 1 dose lyophilisate and 10 vials with 1 ml of solvent
  • Nobivac DHP Lyophilisate and solvent for suspension for injection 50 vials with 1 dose lyophilisate and 50 vials with 1 ml of solvent
  • Nobivac DHP Lyophilisate and solvent for suspension for injection 25 vials with 1 dose lyophilisate and 25 vials with 1 ml of solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V151173
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 28/11/2025
Download
French (PDF)
Published on: 28/11/2025
Download
German (PDF)
Published on: 28/11/2025
Download